Next-Generation Breast Cancer Diagnostic and Screening Market to Grow with a CAGR of 10.61% through 2030
Increasing
government and private investments in cancer research and diagnostics
infrastructure, and technological advancements in next-generation sequencing
and imaging modalities, is expected to drive the Global Next-Generation
Breast Cancer Diagnostic and Screening Market growth in the forecast period, 2026-2030
According to
TechSci Research report, “Next-Generation Breast Cancer Diagnostic and
Screening Market – Global Industry Size, Share, Trends, Competition
Forecast & Opportunities, 2030F”, the Global Next-Generation Breast
Cancer Diagnostic and Screening Market stood at USD 4.65 Billion in 2024 and is expected to reach USD
8.53 Billion by 2030 with a CAGR of 10.61% during the forecast period. This can be due to collaborations and partnerships
among leading companies with a diverse approach to merge the expertise of
individual companies and to strengthen their position in the market.
The aging population is a
driver for the global next-generation breast cancer diagnostic and screening
market. Breast cancer risk significantly increases with age. Most breast cancer
cases occur in women aged 50 and older. As the global population continues to
age, there is a higher prevalence of individuals at an age when breast cancer
risk is elevated. Healthcare guidelines often recommend regular breast cancer
screening for women aged 50 and older. Mammography and other screening methods
become increasingly important as women age, as early detection is associated
with better treatment outcomes. Next-generation breast cancer diagnostic and
screening methods aim to improve early detection, which is particularly crucial
in older populations. Early detection allows for timely treatment interventions
that can be less invasive and have better prognoses. The global geriatric
population is expanding due to increased life expectancy. As individuals live
longer, the likelihood of developing age-related diseases like breast cancer
also rises, driving the demand for advanced diagnostic and screening services.
In March 2023, The RaDaR assay, a liquid biopsy test for molecular/minimal residual disease (MRD), has been made commercially available, according to NeoGenomics, Inc., a top provider of oncology testing and international contract research services. The circulating tumour DNA (ctDNA) that is still present after surgery or other cancer treatments is known as MRD. The CHiRP study, published at ASCO 2022, and data presentations for the TRACER and cTRAK-TN study cohorts at the most recent SABCS conference are just two recent publications that demonstrate the clinical utility of the RaDaR test, particularly in the breast cancer space. The RaDaR assay is a highly sensitive, personalized, tumor-informed technique that monitors up to 48 tumor-specific mutations in cell-free DNA (cfDNA) found in the blood plasma of cancer patients.
Clinical validation is a significant challenge in the global next-generation breast cancer diagnostic and screening market. Clinical validation refers to the rigorous process of demonstrating that a diagnostic or screening test is accurate, reliable, and clinically meaningful for its intended purpose. To establish the accuracy and reliability of a diagnostic test, clinical studies must enroll enough participants. Achieving a large enough sample size with statistical power can be challenging, especially for rare breast cancer subtypes. Long-term follow-up data are essential to assess the test's performance over time. These data are crucial for evaluating the test's ability to predict outcomes, such as disease recurrence or response to treatment. Clinical validation studies often require a "gold standard" for comparison, such as histopathology or clinical outcomes. In the case of breast cancer, obtaining biopsy and pathology data for comparison can be challenging, especially for early-stage or asymptomatic cases.
Browse over XX market data Figures and spread
through XX Pages and an in-depth TOC on "Global Next-Generation Breast Cancer Diagnostic and Screening Market”
The Global Next-Generation
Breast Cancer Diagnostic and Screening Market is segmented into technology, biomarker,
cancer sub-type, offering, end user, regional distribution, and company.
Based on the Technology,
Next-Generation Sequencing (NGS) emerged as the fastest growing segment in the Global
Next-Generation Breast Cancer Diagnostic and Screening Market during the
forecast period. This
growth can be attributed to NGS's ability to provide comprehensive genomic
profiling, enabling precise identification of genetic mutations and alterations
associated with breast cancer. Unlike traditional diagnostic methods, NGS
allows simultaneous sequencing of multiple genes, offering a more detailed and
personalized understanding of tumor biology. This supports the development of
targeted therapies and enhances the effectiveness of treatment decisions,
particularly in complex or metastatic breast cancer cases. Additionally,
technological advancements have made NGS more affordable and accessible,
encouraging its integration into clinical practice. Its high sensitivity,
accuracy, and efficiency in detecting low-frequency variants make it a valuable
tool for early diagnosis, monitoring disease progression, and evaluating
treatment response.
Based
on the Region, Asia-Pacific emerged as the fastest growing region in the Global
Next-Generation Breast Cancer Diagnostic and Screening Market during the forecast period. This is due to
the rapid technological advancement in local healthcare systems and expanding
access to personalized medicine. Increasing adoption of advanced diagnostic
techniques such as Next-Generation Sequencing (NGS), liquid biopsies, and
AI-powered diagnostic platforms has transformed cancer diagnostics in urban
centers. Furthermore, the expanding medical tourism industry in countries like
India, Thailand, and Malaysia has contributed to the adoption of high-end
diagnostic solutions, as international patients seek affordable yet advanced
care. Rising per capita healthcare expenditure and the growth of private
hospitals and specialty clinics offering high-quality oncology services are
making these diagnostics more widely available. Alongside this, the increasing
prevalence of breast cancer due to changing lifestyles, delayed childbearing,
and aging populations has further fueled the demand for next-generation
screening solutions.
Some of the major companies
operating in the Global Next-Generation Breast Cancer Diagnostic and
Screening Market include:
- Abbott Laboratories
- Agendia Inc.
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
- Genomics Co., Ltd.
- CENTOGENE N.V
- Danaher Corporation
- Exact Sciences Corporation
- Hoffmann-La Roche Ltd.
- Illumina, Inc.
- Thermo Fisher Scientific Inc.
- Lucence Diagnostics Pte Ltd.
Download Free Sample Report
Customers can also request 10% free
customization on this report
“The Global
Next-Generation Breast Cancer Diagnostic and Screening Market is expanding due
to the rising emphasis on minimally invasive and non-invasive diagnostic
techniques that improve patient compliance and reduce procedural risks. Liquid
biopsies, which analyze circulating tumor DNA (ctDNA) or other biomarkers from
blood samples, are gaining traction as they offer a less invasive alternative
to traditional tissue biopsies while enabling early detection, real-time
disease monitoring, and assessment of treatment response. The increasing
adoption of these advanced diagnostic methods in clinical practice, supported
by ongoing research and regulatory approvals, is driving market growth by
addressing the demand for safer, faster, and more convenient screening options.,”
said Mr. Karan Chechi, Research Director of TechSci Research, a research-based
management consulting firm.
“Next-Generation Breast
Cancer Diagnostic and Screening Market - Global Industry Size, Share, Trends,
Opportunity, and Forecast, Segmented By Technology (Real-Time PCR,
Immunohistochemistry (IHC), Next-Generation Sequencing (NGS), Fluorescence
In-Situ Hybridization (FISH), Others), By Biomarker (BRCA1/2, ER/PR Receptors,
HER-2, Others), By Cancer Sub-Type (Luminal A, Luminal B, Triple Negative/Basal
Like, Human Epidermal Growth Factor Receptor 2 (HER-2) Enriched), By Offering
(Products, Services), By End User (Hospitals and Clinics, Diagnostic Centers
and Reference Labs, Academic and Research Institutes), By Region and
Competition, 2020-2030F”, has evaluated the future growth potential of Global
Next-Generation Breast Cancer Diagnostic and Screening Market and provides
statistics & information on market size, structure and future market
growth. The report intends to provide cutting-edge market intelligence and help
decision makers take sound investment decisions. Besides, the report also
identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Next-Generation Breast Cancer
Diagnostic and Screening Market.
Contact
TechSci
Research LLC
420
Lexington Avenue, Suite 300,
New York,
United States- 10170
Tel: +1-332-258-6602
Email: sales@techsciresearch.com
Website: www.techsciresearch.com